Managing Schizophrenia With Novel Therapies

CE / CME

Insights Into the Impact of Novel Mechanisms of Action on the Management of Schizophrenia

Nurses: 1.50 Nursing contact hours, including 1.50 hours of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Psychologists: 1.50 APA CE Credits

Social Workers: 1.50 ASWB ACE CE Credits

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: December 23, 2024

Expiration: December 22, 2025

John M. Kane
John M. Kane, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

The novel antipsychotic mechanism of xanomeline-trospium involves:

2.

In clinical trials of olanzapine/samidorphan, what was the key differentiating safety outcome compared to olanzapine alone?

3.

The phase IIb/III EMERGENT trials of xanomeline-trospium demonstrated which efficacy outcome?

4.

Which of the following novel agents is being explored to improve cognitive impairment associated with schizophrenia (CIAS) through modulation of the glycine transporter?

5.

When initiating xanomeline-trospium, the recommended titration approach is:

6.

How knowledgeable do you feel about the safety, efficacy, and clinical use of new medications with novel mechanisms of action for the treatment of schizophrenia?​